-
Express prolongs the life of patients with advanced breast cancer by nearly 16 months, and the long-term clinical results of Novartis CDK4/6 inhibitor are positive
Time of Update: 2022-05-27
▎WuXi AppTec Content Team Editor Today, Novartis announced that its CDK4/6 inhibitor Kisqali (ribociclib) in combination with fulvestrant as first-line therapy in postmenopausal patients with HR+/HER2- advanced or metastatic breast cancer In the phase 3 clinical trial of fulvestrant, the overall survival of patients was extended by nearly 16 months .
-
Express reduces the risk of death in patients with biliary tract cancer by 20%, and the blockbuster PD-L1 inhibitor combination has been granted priority review by the FDA
Time of Update: 2022-05-27
” Reference: [1] Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial.
-
Prof. Wang Ying: Advances in the treatment of acute myeloid leukemia 2021 China Oncology Congress
Time of Update: 2022-05-27
A study published in the New England Journal in 2009 demonstrated for the first time that the increase of daunorubicin (DNR) from 45mg/m² to 90mg/m² significantly improved the remission rate and overall survival (OS) of AML patients aged ≥60 years .
-
AstraZeneca/Daisankyo's blockbuster ADC received FDA approval for express second-line treatment of breast cancer
Time of Update: 2022-05-27
In this trial, Enhertu reduced the risk of disease progression or death by 72% in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane compared with the active control group ([ HR]=0.
-
CAR-T exploration road focuses on the exploration and practice of CAR-T therapy by clinical scientists
Time of Update: 2022-05-27
Tumor patients sought medical treatment, but fortunately met CAR-T therapy, and survived at the end of 2021, the biological treatment department of the Chinese People's Liberation Army General Hospital admitted a 68-year-old diffuse large B-cell lymphoma (DLBCL) patient .
-
From two weeks to one day, the new bioscaffold can quickly generate CAR-T cells in the body, and the anti-cancer effect is faster, stronger and more durable
Time of Update: 2022-05-27
. In a proof-of-concept study of mouse lymphomas, the implantable scaffolds attacked tumors more rapidly than traditional CAR-T cell therapy and translated into stronger and longer-lasting cancer-fighting capabilities .
-
Clin Cancer Res: Pembrolizumab monotherapy for untreated advanced hepatocellular carcinoma
Time of Update: 2022-05-26
Results of cohort 1 of the KEYNOTE-224 trial showed that pembrolizumab was effective and well tolerated in patients with advanced HCC previously treated with sorafenib .
Secondary endpoints included duration of response, disease control rate, time to progression, progression-free survival, overall survival, and safety/tolerability .
-
Clin Cancer Res: Alpha-fetoprotein as a prognostic biomarker for hepatocellular carcinoma treated with Atezolizuma+bevacizumab
Time of Update: 2022-05-26
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.
-
Lancet: The era of comprehensive sublobar resection for small lung cancer is coming!
Time of Update: 2022-05-26
Compared to the previously published preprint article, the final version continues the indications for segmentectomy in the conclusion that segmentectomy should be the standard procedure for small peripheral non-small cell lung cancer, but further fleshes out the study design details and protocol implementation, and supplemented the as-treated analysis of the primary endpoint on the basis of the per-protocal analysis .
-
Leukemia: Comprehensive clinical evaluation of Guadecitabine (SGI-110) in peripheral T-cell lymphoma
Time of Update: 2022-05-26
Guadecitabine therapy has an acceptable overall response rate and drug toxicity profile, and a combination of decitabine analogs targeting histone methyltransferases may provide a potential basis for the treatment of peripheral T-cell lymphoma .
-
On the same day, Express reached a cooperation of more than 2 billion US dollars with two major pharmaceutical companies. What is unique about this cutting-edge protein degradation agent?
Time of Update: 2022-05-26
Image source: Amphista's official website In cooperation with Merck, Germany, the two companies will develop small-molecule protein degraders for 3 targets in the fields of oncology and immunology .
-
Br J Cancer: SBSN: a potential diagnostic and therapeutic target for bladder cancer
Time of Update: 2022-05-26
In conclusion, the results of this study show that SBSN can promote bladder cancer metastasis by activating the EGFR/SRC/STAT3 signaling pathway, which may be a potential diagnostic and therapeutic target for bladder cancer .
-
The most complete tumor molecular targeted drug name and corresponding target list in history
Time of Update: 2022-05-26
In recent years, the state has made great efforts to meet the needs of the common people, attaches great importance to the protection of anti-cancer targeted drugs, and strives to make the drugs available to patients in the shortest possible time .
-
All you want to know about bevacizumab is here
Time of Update: 2022-05-26
Hypertension is the most common adverse reaction during bevacizumab administration, which can be handled by referring to the following management procedures (Figure 1) .
-
Coronary heart disease and cancer, embarrassed!
Time of Update: 2022-05-25
The researchers found that age, hemoglobin, alanine aminotransferase, and fibrinogen levels were independent risk factors for cancer, so they further established a formula for predicting cancer risk in patients with coronary heart disease (Y = 0.
-
European Radiology: Influence of GGO and lymph node status on prognosis of lung cancer
Time of Update: 2022-05-25
5-year overall survival (OS) curves of GGO group and solid group when lymph node metastasis was negative (a) or positive (b) .
5-year overall survival (OS) curves of GGO group and solid group when lymph node metastasis was negative (a) or positive (b) .
-
BMC Med: Apatinib + Oxaliplatin + Capecitabine Neoadjuvant Therapy for Locally Advanced Gastric Cancer/Gastroesophageal Junction Cancer
Time of Update: 2022-05-25
hypertensionIn conclusion, the combination regimen of apatinib, oxaliplatin, and capecitabine as neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma showed reliable efficacy and controllable safety, and it is worth developing 3 Phase clinical trials for further validation .
-
Guidelines Consensus 2022 Guidelines for the diagnosis and treatment of gastric cancer
Time of Update: 2022-05-25
According to the latest data from China in 2020, the incidence and mortality of gastric cancer rank third among various malignant tumors .
The proportion of early gastric cancer in China is very low, only about 20%.
-
Lancet: Adjuvant Pembrolizumab Has Good Efficacy and Safety in Stage II Melanoma (KEYNOTE-716)
Time of Update: 2022-05-25
1016/S0140-6736( 22)00562-1Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
1016/S0140-6736( 22)00562-1Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
-
European Radiology: Radiomics nomogram to identify IDH mutations and loss of ATRX expression in low-grade gliomas
Time of Update: 2022-05-25
In conclusion, a nomogram combining age, gender, and radiomic features provides a non-invasive imaging method for predicting IDH and ATRX mutations in LrGG patients, which can assist in the development of personalized treatment plans .
